IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Sector
Healthcare
Filed
Jul 14, 2026
Attovia Therapeutics, Inc.
Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.
Our lead pipeline candidates target commercially validated pathways and are designed through our ATTOBODY biologics platform to deliver improved treatments relative to the current standards of care.
Leveraging our ATTOBODY platform, we have nominated three product candidates within our first two years, including one currently in the clinic, ATTO-1310.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 14, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 5, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Feb 12, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Dec 19, 2025 | [Cover] Draft Registration Statement |
Contact and headquarters details
Key executives and officers
Tao Fu
Chief Executive Officer, President and Director
Zaneta Odrowaz, Ph.D.
Chief Business Officer, Treasurer, Secretary
Steven Chan
Chief Financial Officer
Petter Veiby
Chief Scientific Officer
Hubert Chen, M.D.
Chief Medical Officer
James Topper, M.D., Ph.D.
Chairman and Director
Mitchell Gold, M.D.
Director
Rebecca Luse.
Director
Aaron Royston, M.D.
Director
John W. Smither
Director